Daewoong Pharmaceutical to Host Exclusive Booth at 'CPHI 2023'... Showcasing Pexuclu and Enblo

Daewoong Pharmaceutical announced on the 19th that it will participate in 'CPHI Worldwide 2023,' held in Barcelona, Spain, from the 24th to the 26th (local time).

Daewoong Pharmaceutical announced on the 19th that it will participate in 'CPHI Worldwide 2023,' the world's largest pharmaceutical and bio event, held in Barcelona, Spain, from the 24th to the 26th (local time). Daewoong Pharmaceutical's booth to be set up at CPHI. [Photo by Daewoong Pharmaceutical]

CPHI is the world's largest pharmaceutical and biotech conference held annually in major European countries. This year, more than 47,000 industry professionals from over 150 countries worldwide are expected to attend.

Daewoong Pharmaceutical plans to set up a solo booth again this year and focus on overseas partnering centered on its self-developed new drugs, including the gastroesophageal reflux disease treatment 'Pexuclu' and the sodium-glucose co-transporter (SGLT)-2 inhibitor class diabetes treatment 'Enblo.' Based on Daewoong Pharmaceutical's technological capabilities and global business competencies, the company aims to strengthen cooperation with overseas partners, expand its global market presence, and discover new business opportunities.

Last year at CPHI, Daewoong Pharmaceutical successfully discovered its first African regional partner for Pexuclu and secured an export contract this year. The company expects to discover new partners and strengthen business with existing partners again this year.

Pexuclu, a potassium-competitive acid blocker (P-CAB) class new drug for gastroesophageal reflux disease, entered the global market by officially launching in the Philippine market just one year after its release. Pexuclu has received marketing authorization in three Latin American countries?Philippines, Ecuador, and Chile?and holds the record as the fastest domestic new drug to apply for marketing authorization in the most countries. To date, marketing authorization applications have been completed in 12 countries, including China, Mexico, Brazil, Saudi Arabia, and Indonesia, and technology export contracts have been signed with a total of 14 countries, including China.

The diabetes treatment Enblo signed export contracts worth 100 billion KRW earlier this year with Brazil and Mexico. Brazil and Mexico represent the largest diabetes markets in Latin America, accounting for 70% of the entire Latin American market, which is approximately 2 trillion KRW in size. Enblo aims to complete local approval procedures by the end of this year and launch in these markets in the second half of next year. In August, it completed marketing authorization application in Saudi Arabia, successfully entering five countries including Indonesia, Thailand, the Philippines, and Vietnam within about 100 days of its official domestic launch.

Seungho Jeon, CEO of Daewoong Pharmaceutical, said, "Daewoong Pharmaceutical, which has succeeded in developing new drugs for two consecutive years based on long-accumulated research and development (R&D) capabilities, plans to further expand its influence in the global market through active collaboration with various partners. Through this event, we will strengthen global partnering and actively promote Daewoong Pharmaceutical’s new drugs and pipeline to solidify our position on the global stage."

This content was produced with the assistance of AI translation services.